Faeth Therapeutics, Inc. received an amended Schedule 13G/A from Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai reporting their ownership of Faeth common stock. As of June 30, 2026, the filers may be deemed to beneficially own 515,335 shares of common stock, representing 2.0% of the company’s outstanding shares. All reported shares are held directly by Trails Edge Biotechnology Master Fund, with Trails Edge Capital as investment manager and Mr. Yehudai exercising voting and investment discretion. The ownership percentages are based on 25,778,754 Faeth common shares outstanding as of June 15, 2026. The filing also notes that the filers hold 5 percent or less of this class of securities.
Khosla Ventures-affiliated entities report a significant passive stake in Faeth Therapeutics, Inc. The group, including Khosla Ventures VI, LP, Khosla Ventures Seed D, LP, Khosla Ventures Associates VI, LLC, Khosla Ventures Seed Associates D, LLC, VK Services, LLC, and Vinod Khosla, reports aggregate beneficial ownership of 2,632,232 shares of Faeth Therapeutics common stock, representing 10.2% of the class.
The holdings are primarily through Khosla Ventures VI, LP with 1,643,349 shares (6.4%) and Khosla Ventures Seed D, LP with 988,883 shares (3.8%). All report shared voting and dispositive power over their respective shares and no sole voting or dispositive power. Ownership percentages are calculated based on 25,840,425 shares outstanding as of July 30, 2026. Each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Faeth Therapeutics, Inc. received an amended ownership report from StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross. These reporting persons now state they beneficially own 0 shares of Faeth Therapeutics common stock, representing 0.0% of the class.
The percentage is calculated using 25,778,754 shares of common stock reported as issued and outstanding as of June 15, 2026. The amendment confirms they have no sole or shared voting or dispositive power over any shares and that they hold 5 percent or less of the class under Schedule 13G rules.
Cambrian Biopharma, Inc., as a holder of Faeth Therapeutics, Inc. common stock, has filed to sell up to 130,142 shares of Faeth Therapeutics common stock through Fidelity Brokerage Services LLC on NASDAQ, with a stated value of $3,642,675.00, beginning on or after July 22, 2026.
The filing also notes that during the past three months, Cambrian Biopharma sold 25,000 shares of Faeth Therapeutics common stock for $500,548.39 on June 1, 2026. The securities being sold were originally acquired in a private placement dated January 10, 2020 for cash.
Faeth Therapeutics, Inc. reported a net loss of $186.2 million for the six months ended June 30, 2026, largely driven by a $133.0 million acquired in-process R&D charge recognized in connection with its February 2026 acquisition of Faeth Therapeutics and related programs.
Excluding that nonrecurring charge, operating costs expanded as research and development expenses rose to $27.1 million and general and administrative expenses to $28.9 million, reflecting integration of the acquired business, higher personnel costs, and stock-based compensation. Cash, cash equivalents and marketable securities totaled $186.4 million as of June 30, 2026, following a $200.0 million Series B preferred stock private placement and subsequent conversion of most preferred shares into common stock.
Post-transaction, legacy Sensei stockholders held about 4.9% of the common equity on a fully diluted basis, former Faeth holders 40.6%, and new private placement investors 54.5%. Management states that the strengthened balance sheet is expected to fund operations through key clinical milestones for lead multi-node PI3K/AKT/mTOR inhibitor PIKTOR in endometrial and HR+/HER2- breast cancer.
Faeth Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and provided clinical and corporate updates. The company highlighted its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing, which it says provides capital to advance its multi-node inhibitor PIKTOR across multiple cancers.
For the quarter, total operating expenses were $18,385 (in thousands), up from $5,206 (in thousands) a year earlier, driven by research and development of $9,180 (in thousands) and general and administrative expenses of $9,205 (in thousands). Net loss was $16,007 (in thousands), compared with $4,936 (in thousands), or $2.84 net loss per share versus $3.91. Cash and cash equivalents were $26,903 (in thousands) and marketable securities were $159,538 (in thousands) as of June 30, 2026.
Operationally, Faeth reported that topline results from its Phase 2 PIK-201 trial in advanced endometrial cancer are on track for year-end 2026, and that the first patient was dosed in its Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026, with initial data anticipated in 2027.
Faeth Therapeutics, Inc. has an initial beneficial ownership report from entities affiliated with Khosla Ventures, including Khosla Ventures VI, L.P. and Khosla Ventures Seed D, L.P., relating to Common Stock.
The securities are held of record by these funds, with Khosla Ventures Associates VI, LLC and Khosla Ventures Seed Associates D, LLC as general partners, and VK Services, LLC and Vinod Khosla positioned to exercise voting and investment control. Each reporting person may be deemed to have indirect beneficial ownership but expressly disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants under its 2026 Equity Incentive Plan for employees who were employed as of February 19, 2026, including key executives.
The Chief Executive Officer received options for 398,018 shares, the General Counsel 84,766 shares and the Senior Vice President, Finance 30,824 shares. Each option has an exercise price equal to the closing price of the common stock on the grant date and vests in a single tranche only after a Stock Price Hurdle of $70.00 per share is achieved during a Performance Period that ends on the fourth anniversary of the grant date and at least one year has elapsed, subject to continued service. Unvested options are forfeited if the hurdle is not met or service ends, while a qualifying change in control with per-share consideration of at least $70.00 accelerates vesting.
Faeth Therapeutics, Inc. granted PAO Josiah Craver a performance-based stock option covering 30,824 shares of common stock at an exercise price of $28.37 per share. The option becomes exercisable only if the average Nasdaq closing price reaches $70.00 over 30 consecutive days and at least one year has passed, and is forfeited if the stock price hurdle is not achieved by the fourth anniversary or not met in connection with a qualifying Change in Control. Following this award, Craver holds 30,824 of these options directly.
Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036. The option vests only if a sustained $70.00 stock-price hurdle and time-and-service conditions are met. In a qualifying Change in Control where per-share consideration is at least $70.00, it vests in full; if the $70.00 hurdle is not achieved by the fourth anniversary of grant, or not deemed achieved in connection with a Change in Control, the option is forfeited.